BR112022018449A2 - Cocristais de ácido carboxílico de (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-il carbamoil) ciclopentano - Google Patents
Cocristais de ácido carboxílico de (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-il carbamoil) ciclopentanoInfo
- Publication number
- BR112022018449A2 BR112022018449A2 BR112022018449A BR112022018449A BR112022018449A2 BR 112022018449 A2 BR112022018449 A2 BR 112022018449A2 BR 112022018449 A BR112022018449 A BR 112022018449A BR 112022018449 A BR112022018449 A BR 112022018449A BR 112022018449 A2 BR112022018449 A2 BR 112022018449A2
- Authority
- BR
- Brazil
- Prior art keywords
- thiazol
- carbamoyl
- cyano
- phenyl
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/02—Salts; Complexes; Addition compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382194.7A EP3882240A1 (en) | 2020-03-16 | 2020-03-16 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| PCT/EP2021/056506 WO2021185748A1 (en) | 2020-03-16 | 2021-03-15 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018449A2 true BR112022018449A2 (pt) | 2022-11-01 |
Family
ID=69953938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018449A BR112022018449A2 (pt) | 2020-03-16 | 2021-03-15 | Cocristais de ácido carboxílico de (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-il carbamoil) ciclopentano |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12384754B2 (enExample) |
| EP (2) | EP3882240A1 (enExample) |
| JP (1) | JP7779846B2 (enExample) |
| KR (1) | KR20220154791A (enExample) |
| CN (1) | CN115298169B (enExample) |
| AU (1) | AU2021237686B2 (enExample) |
| BR (1) | BR112022018449A2 (enExample) |
| CA (1) | CA3171894C (enExample) |
| DK (1) | DK4121419T3 (enExample) |
| ES (1) | ES3002084T3 (enExample) |
| FI (1) | FI4121419T3 (enExample) |
| HR (1) | HRP20241515T1 (enExample) |
| HU (1) | HUE068886T2 (enExample) |
| LT (1) | LT4121419T (enExample) |
| MX (1) | MX2022011530A (enExample) |
| PL (1) | PL4121419T3 (enExample) |
| PT (1) | PT4121419T (enExample) |
| RS (1) | RS66214B1 (enExample) |
| SI (1) | SI4121419T1 (enExample) |
| WO (1) | WO2021185748A1 (enExample) |
| ZA (1) | ZA202211247B (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331220B1 (es) * | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| US8779146B2 (en) | 2010-04-28 | 2014-07-15 | Nuformix Limited | Cilostazol cocrystals and compositions |
| HRP20211104T1 (hr) | 2017-03-06 | 2021-10-15 | Palobiofarma, S.L. | Aminska sol (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksilne kiseline |
-
2020
- 2020-03-16 EP EP20382194.7A patent/EP3882240A1/en not_active Withdrawn
-
2021
- 2021-03-15 AU AU2021237686A patent/AU2021237686B2/en active Active
- 2021-03-15 DK DK21710531.1T patent/DK4121419T3/da active
- 2021-03-15 PT PT217105311T patent/PT4121419T/pt unknown
- 2021-03-15 JP JP2022555805A patent/JP7779846B2/ja active Active
- 2021-03-15 CA CA3171894A patent/CA3171894C/en active Active
- 2021-03-15 ES ES21710531T patent/ES3002084T3/es active Active
- 2021-03-15 SI SI202130224T patent/SI4121419T1/sl unknown
- 2021-03-15 MX MX2022011530A patent/MX2022011530A/es unknown
- 2021-03-15 PL PL21710531.1T patent/PL4121419T3/pl unknown
- 2021-03-15 CN CN202180021708.3A patent/CN115298169B/zh active Active
- 2021-03-15 RS RS20241203A patent/RS66214B1/sr unknown
- 2021-03-15 FI FIEP21710531.1T patent/FI4121419T3/fi active
- 2021-03-15 US US17/906,367 patent/US12384754B2/en active Active
- 2021-03-15 HR HRP20241515TT patent/HRP20241515T1/hr unknown
- 2021-03-15 WO PCT/EP2021/056506 patent/WO2021185748A1/en not_active Ceased
- 2021-03-15 KR KR1020227035871A patent/KR20220154791A/ko active Pending
- 2021-03-15 BR BR112022018449A patent/BR112022018449A2/pt unknown
- 2021-03-15 EP EP21710531.1A patent/EP4121419B1/en active Active
- 2021-03-15 LT LTEPPCT/EP2021/056506T patent/LT4121419T/lt unknown
- 2021-03-15 HU HUE21710531A patent/HUE068886T2/hu unknown
-
2022
- 2022-10-13 ZA ZA2022/11247A patent/ZA202211247B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021185748A1 (en) | 2021-09-23 |
| PL4121419T3 (pl) | 2025-02-17 |
| CN115298169B (zh) | 2024-11-19 |
| EP4121419B1 (en) | 2024-08-14 |
| PT4121419T (pt) | 2024-11-18 |
| ZA202211247B (en) | 2023-12-20 |
| US12384754B2 (en) | 2025-08-12 |
| AU2021237686A1 (en) | 2022-10-06 |
| SI4121419T1 (sl) | 2025-02-28 |
| JP2023517722A (ja) | 2023-04-26 |
| HRP20241515T1 (hr) | 2025-01-03 |
| HUE068886T2 (hu) | 2025-02-28 |
| CA3171894C (en) | 2025-03-11 |
| RS66214B1 (sr) | 2024-12-31 |
| JP7779846B2 (ja) | 2025-12-03 |
| CA3171894A1 (en) | 2021-09-23 |
| MX2022011530A (es) | 2022-10-13 |
| FI4121419T3 (fi) | 2024-11-04 |
| DK4121419T3 (da) | 2024-10-28 |
| KR20220154791A (ko) | 2022-11-22 |
| AU2021237686B2 (en) | 2026-04-09 |
| US20230183195A1 (en) | 2023-06-15 |
| LT4121419T (lt) | 2024-11-25 |
| EP3882240A1 (en) | 2021-09-22 |
| EP4121419A1 (en) | 2023-01-25 |
| ES3002084T3 (en) | 2025-03-06 |
| CN115298169A (zh) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002963A1 (es) | Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer | |
| DOP2023000252A (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
| BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
| BRPI0720588B8 (pt) | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
| BR112013011634A2 (pt) | derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c] | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BR112019002007A2 (pt) | composições farmacêuticas, processo para a fabricação de grânulos, processo para a fabricação de uma composição farmacêutica, processo para a preparação de monocloridrato de ipatasertib amorfo, método para o tratamento de distúrbios hiperproliferativos, utilização de uma composição farmacêutica e presente invenção | |
| BR112022024045A2 (pt) | Moduladores il-17a | |
| BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| BR112016027674A2 (pt) | Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112019023109A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| WO2018097570A3 (ko) | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| BR112018013408A2 (pt) | derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |